Literature DB >> 10886222

Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma.

V S Hornsey1, P Krailadsiri, S MacDonald, J Seghatchian, L M Williamson, C V Prowse.   

Abstract

Levels of factor VIII (FVIII) and fibrinogen were assessed in control cryoprecipitate and cryoprecipitate prepared in two centres from plasma subjected to methylene blue (MB) photochemical virus inactivation. The level of coagulation FVIII activity was reduced in plasma by approximately 30% after MB photoinactivation, with only 44% (centre A) and 31% (centre B) of units meeting the current UK specification of 0.7 iu/ml. A revised specification of 0.5 iu/ml is suggested. Losses of less than 11% were seen for von Willebrand factor (VWF)-related activities. Cryoprecipitate prepared from group O or group A MB-treated plasma contained 27-40% less FVIII than control units. This reflected the lower levels in MB-treated plasma. The concentrating power of the cryoprecipitation process was not reduced for FVIII or fibrinogen in MB-treated units. MB cryoprecipitate from centre A still met the UK guideline specification for FVIII and fibrinogen content, whereas at centre B only 62.5% of the group O cryoprecipitates contained > 70 iu FVIII/unit. This may reflect the lower product volume and lower FVIII content of group O plasma used at centre B and suggests that maintenance of total coagulation factor recovery in MB-treated cryoprecipitate will require the higher product volume.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886222     DOI: 10.1046/j.1365-2141.2000.02078.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Fibrinogen replacement therapy: a critical review of the literature.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2011-11-15       Impact factor: 3.443

2.  The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation.

Authors:  Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

3.  Factors affecting the quality of cryoprecipitate.

Authors:  Rajeswari Subramaniyan; Neelam Marwaha; Ashish Jain; Jasmina Ahluwalia
Journal:  Asian J Transfus Sci       Date:  2017 Jan-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.